Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07815288) titled 'Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases' on Sept. 6.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking University Cancer Hospital & Institute
Condition:
Colorectal Adenocarcinoma Metastatic in the Liver
Intervention:
Drug: Retlirafusp alfa Combined with Targeted Therapy and Chemotherapy
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 30, 2026
Target Sample Size: 80
...